Product Information
TRI-NYMYO 28 TABLET is a generic product labeled by Mayne Pharma, priced at $0.1415 per EA under NDC 51862064601. Its NADAC has been published 187 times since Oct 20, 2021.
Manufacturer
Mayne PharmaNDC
51862064601
Classification
Generic
Dosage Form
KIT
Last Updated
4/23/2025
Approval Type
Generic (ANDA)
FDA Application
ANDA090524On Market Since
10/24/2020
Price Statistics
The NADAC for TRI-NYMYO 28 TABLET has been published 187 times since Oct 20, 2021, and over the history we have for it it has declined 22.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1415 per EA |
|---|---|
| All-time high | $0.1848 (Dec 15, 2021) |
| All-time low | $0.1072 (Jul 17, 2024) |
| Median price | $0.1402 |
| Average price | $0.1425 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 187 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
The matcher finds 7 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 7 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 26% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRI-NYMYO 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-NYMYO 28 TABLET, manufactured by Mayne Pharma, is $0.1415 per EA (NDC 51862064601), effective May 14, 2025.
How has the price of TRI-NYMYO 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-NYMYO 28 TABLET has declined 22.0%. It has been tracked across 187 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for TRI-NYMYO 28 TABLET?
Since Oct 20, 2021, the NADAC for TRI-NYMYO 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.1848 (Dec 15, 2021), with a median of $0.1402 per EA.
Are there cheaper alternatives to TRI-NYMYO 28 TABLET?
Yes. 7 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1049 per EA — about 26% below TRI-NYMYO 28 TABLET.
Who manufactures TRI-NYMYO 28 TABLET?
TRI-NYMYO 28 TABLET (NDC 51862064601) is labeled by Mayne Pharma, and CMS classifies it as a generic product.
Related Drugs
Same classification